https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u107229Tue, 06 Oct 2026 18:55:19 +0000The FDA cleared blood tests from Roche and C2N Diagnostics to identify amyloid pathology in patients. These tools allow clinicians to detect brain plaques associated with Alzheimer's disease before a standard diagnosis would typically occur. The PrecivityAD2 test is approved for adults as young as 40. These diagnostics provide a less invasive alternative to previous methods for ruling in or ruling out the pathology of cognitive decline.Why it mattersEarly detection of amyloid plaques allows for earlier intervention in Alzheimer's treatment. These blood-based tests replace more invasi https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u100378Sun, 04 Oct 2026 22:40:46 +0000The US FDA cleared four blood-based Alzheimer's tests to help clinicians identify amyloid pathology in patients. These include the Elecsys pTau217 test developed by Roche and Eli Lilly, as well as C2N Diagnostics' PrecivityAD2. These tools provide a less invasive method for physicians to evaluate cognitive decline and predict brain changes associated with the disease. PrecivityAD2 is approved for use in adults as young as 40. The clearance allows for more accessible rule-in and rule-out procedures for Alzheimer's pathology compared to previous diagnostic methods.Why it mattersTr https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u95538Fri, 02 Oct 2026 22:17:45 +0000The US FDA has cleared four blood-based Alzheimer's tests, including Roche's Elecsys pTau217 developed with Eli Lilly, and C2N Diagnostics' PrecivityAD2. These tests help clinicians rule in and rule out amyloid pathology in Alzheimer's disease patients. The clearance provides physicians with less invasive diagnostic tools to evaluate cognitive decline and predict brain changes associated with Alzheimer's. PrecivityAD2 is indicated for adults as young as 40.Why it mattersThe FDA's clearance of these blood tests marks a significant development in Alzheimer's di https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u91992Thu, 01 Oct 2026 00:03:01 +0000The US FDA has cleared Roche's Elecsys pTau217 blood test, developed in collaboration with Eli Lilly, to help clinicians rule in and rule out amyloid pathology in Alzheimer's disease patients. This test is the first single-biomarker blood test for this purpose. The clearance provides physicians with a less invasive diagnostic tool to evaluate cognitive decline and predict brain changes associated with Alzheimer's.Why it mattersAlzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide. Early diagnosis and detection are crucial for effectiv https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u72391Thu, 17 Sep 2026 07:15:21 +0000The US Food and Drug Administration cleared the Elecsys pTau217 blood test, developed by Roche in collaboration with Eli Lilly. This assay serves as the first single-biomarker blood test to help clinicians rule in and rule out amyloid pathology in patients with Alzheimer's disease. The clearance provides physicians with a less invasive diagnostic tool to evaluate cognitive decline and predict brain changes associated with the condition.Why it mattersTraditional Alzheimer's assessment methods often involve invasive or costly procedures to detect amyloid pathology. Blood-based biomarke https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u58488Sat, 05 Sep 2026 22:07:15 +0000The US FDA cleared the Elecsys pTau217 blood test, a collaboration between Roche and Eli Lilly, to help physicians identify signs of Alzheimer's disease. The test targets adults aged 55 and older who show symptoms of cognitive decline. As the first single-biomarker blood test of its kind, it predicts the likelihood of Alzheimer's-related brain changes. Labcorp and Quest Diagnostics plan to provide the test to healthcare providers, offering a less invasive alternative to traditional assessment methods.Why it mattersTraditional Alzheimer's assessments often rely on expensive or in https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u50564Fri, 28 Aug 2026 07:10:39 +0000The US FDA cleared the Elecsys pTau217 blood test, developed by Roche and Eli Lilly, to identify signs of Alzheimer's disease in adults 55 and older experiencing cognitive decline. This tool uses a single biomarker to predict the likelihood of Alzheimer's-related changes rather than providing a formal diagnosis. Labcorp and Quest Diagnostics intend to offer the test to healthcare providers.Why it mattersTraditional Alzheimer's detection often requires more invasive or expensive procedures. This blood test provides a less intrusive method for doctors to screen patients. It marks https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u49487Thu, 27 Aug 2026 04:06:19 +0000The US FDA has cleared the Elecsys pTau217 blood test developed by Roche and Eli Lilly to help detect signs of Alzheimer's disease in adults aged 55 and older with cognitive decline. The test predicts the likelihood of Alzheimer's-related changes using a single biomarker but does not provide a formal diagnosis. Labcorp and Quest Diagnostics plan to offer the test.Why it mattersThis clearance is significant for Alzheimer's diagnosis, as it provides a simpler way to assess Alzheimer's-related changes. The test is designed to aid the evaluation process for patients reporting c https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u48407Tue, 25 Aug 2026 12:12:14 +0000The US Food and Drug Administration cleared the Elecsys pTau217 blood test developed by Roche and Eli Lilly to help detect signs of Alzheimer's disease. The test is intended for adults age 55 and older who are experiencing cognitive decline. While the test predicts the likelihood of Alzheimer's-related changes using a single biomarker, it does not provide a formal diagnosis of the brain disorder. The tool is designed to aid the evaluation process for patients reporting cognitive issues.Why it mattersTraditional Alzheimer's detection often requires more invasive or expensive proc